News articles about Innoviva (NASDAQ:INVA) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Innoviva earned a media sentiment score of 0.21 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.2865771247663 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Innoviva, Inc. (NASDAQ:INVA) – Hot Stock’s Watch List – Nasdaq Journal (press release) (nasdaqjournal.com)
- Investor Interest Amplifies Stock EV For Innoviva, Inc. (NasdaqGS:INVA) – Clawson News (clawsonnews.com)
- Innoviva Inc (INVA) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- EPS for Innoviva, Inc. (INVA) Expected At $0.45; Community Health Systems (CYH) Sentiment Is 1.01 – Hill Country Times (hillcountrytimes.com)
- Innoviva Inc (INVA) Expected to Announce Quarterly Sales of $66.75 Million (americanbankingnews.com)
Several equities analysts have commented on the stock. Robert W. Baird reissued a “hold” rating and issued a $13.00 price target on shares of Innoviva in a research report on Tuesday, October 24th. BidaskClub raised shares of Innoviva from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Deutsche Bank assumed coverage on shares of Innoviva in a research report on Monday, November 20th. They issued a “hold” rating and a $13.00 price target for the company. Zacks Investment Research cut shares of Innoviva from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Morgan Stanley restated an “underweight” rating and issued a $8.00 price objective (up from $7.00) on shares of Innoviva in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $13.50.
Shares of Innoviva (NASDAQ INVA) opened at $14.83 on Friday. Innoviva has a fifty-two week low of $10.30 and a fifty-two week high of $14.91. The firm has a market cap of $1,552.18, a price-to-earnings ratio of 17.05 and a beta of 2.52. The company has a debt-to-equity ratio of -2.59, a current ratio of 6.71 and a quick ratio of 6.71.
Innoviva (NASDAQ:INVA) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.21 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.13). Innoviva had a net margin of 52.91% and a negative return on equity of 33.55%. The firm had revenue of $48.64 million during the quarter, compared to analyst estimates of $57.18 million. During the same quarter in the previous year, the business posted $0.13 earnings per share. Innoviva’s revenue for the quarter was up 46.0% compared to the same quarter last year. sell-side analysts anticipate that Innoviva will post 1.08 earnings per share for the current fiscal year.
In other news, VP George B. Abercrombie sold 5,215 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $13.26, for a total value of $69,150.90. Following the sale, the vice president now directly owns 263,866 shares in the company, valued at approximately $3,498,863.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Eric Desparbes sold 15,285 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $13.28, for a total transaction of $202,984.80. Following the completion of the sale, the chief financial officer now owns 337,027 shares in the company, valued at $4,475,718.56. The disclosure for this sale can be found here. Insiders sold a total of 32,522 shares of company stock worth $429,985 over the last 90 days. Company insiders own 1.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Innoviva (INVA) Earning Somewhat Favorable News Coverage, Study Shows” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be accessed at https://transcriptdaily.com/2018/01/20/innoviva-inva-earning-somewhat-favorable-news-coverage-study-shows.html.
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.